New trial tests precision radiation to fight spread bladder cancer
NCT ID NCT07413523
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is for people with bladder cancer that has spread to a small number of other body parts (up to 3 spots). It compares standard treatment (chemotherapy or immunotherapy) alone versus standard treatment plus a precise, high-dose radiation therapy called SBRT. The goal is to see if adding SBRT helps control the cancer better. About 44 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stereotactic body radiation therapy (SBRT)
What this could lead to
If it works, this could show that adding targeted radiation to standard therapy helps control bladder cancer that has spread to a few places, potentially improving outcomes.
What could go wrong
This is a small early-phase trial with only 44 participants, so results may not apply widely. Radiation can cause side effects, and it is unclear if it will meaningfully improve survival or quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Humanitas Research Hospital
RECRUITINGRozzano, Milan, 20089, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••